Citi Pharma Past Earnings Performance
Past criteria checks 2/6
Citi Pharma has been growing earnings at an average annual rate of 34%, while the Pharmaceuticals industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 30.2% per year. Citi Pharma's return on equity is 12.2%, and it has net margins of 5.3%.
Key information
34.0%
Earnings growth rate
21.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 20.2% |
| Revenue growth rate | 30.2% |
| Return on equity | 12.2% |
| Net Margin | 5.3% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Citi Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 12,397 | 658 | 330 | 0 |
| 31 Mar 23 | 11,050 | 619 | 295 | 0 |
| 31 Dec 22 | 11,110 | 733 | 275 | 0 |
| 30 Sep 22 | 10,907 | 700 | 263 | 0 |
| 30 Jun 22 | 9,780 | 654 | 361 | 0 |
| 31 Mar 22 | 9,369 | 650 | 312 | 0 |
| 31 Dec 21 | 8,401 | 542 | 292 | 0 |
| 30 Sep 21 | 6,508 | 367 | 321 | 0 |
| 30 Jun 21 | 5,795 | 352 | 201 | 0 |
| 31 Mar 21 | 5,198 | 296 | 248 | 0 |
| 30 Jun 20 | 3,528 | 143 | 173 | 0 |
| 30 Jun 19 | 2,607 | 28 | 184 | 0 |
| 30 Jun 18 | 2,003 | 117 | 121 | 0 |
Quality Earnings: CPHL has a high level of non-cash earnings.
Growing Profit Margin: CPHL's current net profit margins (5.3%) are lower than last year (6.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CPHL's earnings have grown significantly by 34% per year over the past 5 years.
Accelerating Growth: CPHL's earnings growth over the past year (0.7%) is below its 5-year average (34% per year).
Earnings vs Industry: CPHL earnings growth over the past year (0.7%) exceeded the Pharmaceuticals industry -2.1%.
Return on Equity
High ROE: CPHL's Return on Equity (12.2%) is considered low.